Using distinct amino acids in the background of BCR–ABL–triggered CML, this study illustrates the efficacy of the N-end rule–based PROTAC in disease relevant settings in vitro and in vivo for the first time. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.